

1 **An economic evaluation of two cervical screening algorithms in Belgium: HR-HPV primary compared**
2 **to HR-HPV and liquid-based cytology (LBC) co-testing**

3 Running head:

4 Economic evaluation of cervical screening algorithms in Belgium

5 Authors

6 Caroline Dombrowski¹, Claire Bourgain², Yixuan Ma¹, Anne Meiwald¹, Amy Pinsent¹, Birgit Weynand²
7 Katy ME Turner¹, Susie Huntington¹, *Elisabeth J Adams¹, Johannes Bogers^{2,3}, Romaric Croes⁴, Shaira
8 Sahebal².

9

10 Author affiliations

11 ¹Aquarius Population Health, London, UK

12 ²The Cytology Working Group of the Belgian Society of Pathology, Belgium

13 ³University of Antwerp, Laboratory for Cell Biology and Histology, Antwerp, Belgium

14 ⁴Belgian Society of Pathology, Belgium

15

16 *Corresponding author: Dr Elisabeth Adams

17 Aquarius Population Health, Unit 29 Tileyard Studios, London N7 9AH, UK

18 Email: Elisabeth.Adams@aquariusph.com, Telephone: +44 (0) 207 993 2930

19

20 Ethics statement

21 Ethical review and approvals were not required or sought as this paper reports a theoretical health
22 economic evaluation of two cervical screening algorithms and patients were not involved in the
23 evaluation.

24 Source of Funding and Competing Interests

25 Aquarius Population Health received funding from Hologic for this study; the design, results and
26 interpretation of the study are independent and the authors' own.

27 At the time of writing, CD, YM, AM, AP, KT, SH and EA were all part of Aquarius Population Health Ltd, an
28 independent consultancy which has previously worked on projects related to diagnostic screening for
29 numerous commercial and non-commercial organisations.

30 CB, BW, JB, RC, SS have no competing interests to disclose.

31

32 Author Contribution Statement

33 CD: Methodology, analysis, project administration, interpretation, supervision, writing – review &
34 editing; CB: Writing – review & editing; YM: validation, analysis, visualization, writing – original draft,
35 AM: Conceptualization, methodology, analysis, data curation; AP: Conceptualization, methodology,
36 analysis, data curation; BW: Writing – review & editing; KT: Conceptualization, supervision. SH:
37 supervision, writing – review & editing; EA: Conceptualization, supervision, writing – review & editing;
38 JB: Writing – review & editing; RC: Writing – review & editing; SS Writing – review & editing.

39 All authors reviewed and approved the final manuscript.

40

41 **Abstract**

42 **Objective:** To assess the costs and benefits of two algorithms for cervical cancer screening in Belgium 1)
43 high-risk human papillomavirus (HR-HPV) primary screening and 2) HR-HPV and liquid-based cytology
44 (LBC) co-testing.

45 **Methods:** A decision tree was adapted from published work and parameterised using HORIZON study
46 data and Belgian cost and population data. The theoretical model represents two different screening
47 algorithms for a cohort of 577,846 women aged 25 – 64 attending routine cervical screening. Scenario
48 analyses were used to explore the impact of including vaccinated women and alternative pricing
49 approaches. Uncertainty analyses were conducted.

50 **Results:** The cost per woman screened was €113.50 for HR-HPV primary screening and €101.70 for co-
51 testing, representing a total cost of €65,588,573 and €58,775,083 respectively for the cohort; a 10%
52 difference. For one screening cycle, compared to HR-HPV primary, co-testing resulted in 13,173 more
53 colposcopies, 67,731 more HR-HPV tests and 477,020 more LBC tests. Co-testing identified 2,351 more
54 CIN2+ cases per year (27% more than HR-HPV primary) and 1,602 more CIN3+ cases (24% more than HR-
55 HPV primary) than HR-HPV primary.

56 **Conclusion:** In Belgium, a co-testing testing algorithm could increase cervical precancer detection rates
57 compared to HR-HPV primary. Co-testing would cost less than HR-HPV primary if the cost of the HPV
58 test and LBC were cost-neutral compared to the current cost of LBC screening but would cost more if
59 the cost per HPV test and LBC were the same in both co-testing and HR-HPV primary strategies.

60 **Keywords:** HR-HPV infection; Cervical Cancer screening; HPV; Co-testing; Belgium; Economic Model

61 Introduction

62 Cervical cancer, caused by high-risk human papillomavirus (HR-HPV), is a leading cause of mortality in
63 women (WHO, 2022). While not all HR-HPV infections result in cancer, persistent HR-HPV infection can
64 lead to cervical abnormalities, which if not detected and treated, progress to invasive cervical cancer
65 (Monsonogo et al., 2004).

66 The World Health Organization (WHO) has set a global target to eliminate cervical cancer through a
67 combined approach of prevention (HR-HPV vaccination), testing (cervical screening programmes) and
68 treatment (WHO, 2020a). Cervical screening can identify HR-HPV and cervical cell abnormalities that,
69 when detected at an early stage, can be managed to reduce the risk of disease progression and
70 mortality (Jansen et al., 2020). While many high-income countries have offered high-quality cervical
71 screening via Pap smear tests for many years, technological advancements in testing and interventions,
72 including HR-HPV vaccination, have led countries to review their existing programmes (Anttila et al.,
73 2004). Studies demonstrated the benefits of HPV-based screening (Ronco et al., 2014) and some
74 countries have or will transition from cytology-based screening to HR-HPV primary testing with LBC
75 (liquid-based cytology) following an HR-HPV positive result (Maver and Poljak, 2020)). Other countries,
76 like the United States (US) and Germany (Fontham et al., 2020; Khaja et al., 2022), have chosen to
77 implement co-testing (using LBC and HR-HPV testing concurrently) as studies suggest that co-testing can
78 detect more people who are HR-HPV negative but have abnormal cytology. Approximately 3-14%
79 (precancer) or 13-18% (cancer) cases are HPV negative and are therefore missed using HR-HPV primary
80 testing (Austin R.M. et al., 2018; Vasilyeva et al., 2021, Blatt et al., 2015a; Kaufman et al., 2020). F
81 Data from a large study in Belgium in 2010 indicates the prevalence of HR-HPV is around 13% in women
82 (Depuydt et al., 2010), with approximately 3,000 cases of carcinoma *in situ* (Arbyn Marc et al., 2015)
83 and 600 new cases of invasive cervical cancer diagnosed annually (Bruni et al., 2023). Although access to

84 screening is available, there is currently no centrally organised national cervical screening programme.
85 Screening coverage was reported as 61% nationally for the period 2004-2006 (Arbyn et al., 2014) and
86 more recently, as 62.6% in Flanders (Flemish Department of care, 2021). Regional health authorities are
87 responsible for screening and their approaches vary. In Flanders, women aged 25 – 64 receive an LBC
88 test every three years in a semi-organised screening programme, while in French-speaking regions,
89 screening is opportunistic (Van Kerrebroeck and Makar, 2016). In 2020, a pilot screening program for
90 women aged 25-64 launched in Wallonia. HR-HPV vaccination coverage varies considerably by region
91 from 91% in Flanders (Thiry et al., 2019) to 31-50% in French-speaking regions (Bonanni et al., 2020).
92 As the Belgium government considers moving from a regionally organised cytology-based screening to a
93 national HR-HPV primary screening programme, it is important to consider the costs and potential
94 benefits of different screening algorithms. Health economic models can be used to inform decision
95 making by quantifying the outcomes of different screening algorithms within a given setting (Mendes et
96 al., 2015). This study uses a decision tree model to assess the health and economic outcomes of a HR-
97 HPV primary screening algorithm compared to co-testing algorithm in Belgium.

98 **Methods**

99 Model overview

100 A decision tree model was developed in Excel v2202 (Microsoft, Redmond, WA, USA) to simulate
101 potential cervical screening algorithms for Belgium, comparing HR-HPV primary with co-testing
102 algorithms. A cost-consequence analysis was undertaken from the perspective of the Belgian healthcare
103 system.

104 Cervical screening algorithm

105 A national cervical screening algorithm for HR-HPV primary screening in Belgium has not yet been
106 finalised, therefore theoretical cervical screening algorithms were developed for the Belgium setting

107 **(Figure 1)**; the HR-HPV primary algorithm was adapted from the Netherlands screening algorithm (RIVM,
108 2021) and the co-testing algorithm was adapted from screening algorithms in Germany and Luxembourg
109 (Iftner, 2021; Secrétariat du Conseil Scientifique, 2019).

110 In the HR-HPV primary algorithm, women have a cervical sample taken which is tested for HR-HPV
111 **(Figure 1)**. Those who test negative return for re-testing every 5 years (hereafter referred to as the
112 routine screening cycle) and HR-HPV positive samples are tested using reflex-LBC. Those with normal
113 baseline LBC results return after 6 months for repeat LBC testing. Those with abnormal (non-NILM) LBC
114 results are referred for colposcopy. If the colposcopy and histology results are abnormal, they receive
115 appropriate treatment, or if the results are normal, they return for a follow-up LBC in 12 months.

116 In the co-testing algorithm, all cervical samples have HR-HPV testing and LBC simultaneously **(Figure 1)**.
117 Those with HR-HPV negative and normal LBC results return to the routine screening cycle (5 years).
118 Those with HR-HPV positive results and normal LBC results have a repeat co-test after 12 months and
119 those with repeat HR-HPV positive and/or LBC abnormal results are referred for colposcopy, whereas
120 those with negative results return to routine recall. At routine testing, those with abnormal LBC results
121 are referred for colposcopy immediately and if the biopsy is negative, return for an additional LBC after
122 6 months; those with normal LBC results return for repeat co-testing after 18 months.

123 Like the German co-testing algorithm, the co-testing algorithm includes a medium-risk group to simulate
124 a more conservative follow-up of women who are HR-HPV negative and have borderline or low-grade
125 LBC results. Instead of direct referral to colposcopy, a proportion of those with HR-HPV negative and
126 abnormal but low-grade LBC baseline results receive follow-up LBC testing at 6 months **(Table 1)**, and if
127 LBC results are normal, return for repeat co-testing at 18 months. Those with abnormal LBC results are
128 referred to colposcopy. The remainder are assumed to have higher grade LBC results and are directly
129 referred to colposcopy. Patients exit the algorithm to return to routine recall after negative co-testing

130 results, after the second colposcopy with negative biopsy results, or after treatment after the biopsy. All
131 samples were assumed to give conclusive test results, with no inadequate samples.

132 Patient and public involvement

133 This is a theoretical analysis, using only published and routinely available data. No patients were
134 involved at any stage of this study and only published aggregate patient data was used.

135 Outcomes

136 The primary outcomes of the study were total screening costs (from attendance at screening to
137 treatment for cervical intraepithelial neoplasia (CIN1-CIN3)), average cost per complete screen, cost per
138 CIN2+ and CIN3+ case, total number of colposcopies, number of HR-HPV and LBC tests performed, and
139 number of cervical precancer and cancer cases diagnosed.

140 The secondary outcomes were the total cost of colposcopies, total cost of HR-HPV and LBC tests, and
141 cost of treatment of CIN1, CIN2 and CIN3. The difference in costs and outcomes between the two
142 screening algorithms were calculated (HR-HPV primary and co-testing).

143 Population

144 The simulated population represents 577,846 women in Belgium aged 25-64 attending screening in one
145 year, assuming a 5-year recall period. The most inclusive language for cervical screening is “women and
146 people with a cervix” (Gov.uk, 2022); the term ‘women’ is used throughout this paper to reflect EU
147 screening guidelines (European Commission, 2022) and Belgian literature (Arbyn Marc et al., 2015).

148 Model parameters

149 The model parameter inputs are detailed in **Table 1** and Error! Reference source not
150 found. **Supplemental Table 1** and include screening coverage, probability of detecting HR-HPV and pre-

151 cancer (by age group), testing probabilities (HR-HPV primary, cytology, colposcopy), loss to follow up
152 and cost inputs.

153 *Transition probability inputs*

154 There is limited published individual patient-level data reporting long-term health outcomes associated
155 with different testing algorithms and no Belgian-specific data. The HORIZON study (Rebolj et al., 2016,
156 2015) (see **Supplemental Tables** for details), was conducted in Denmark and assessed 4,128 cervical
157 samples using four different HR-HPV assays and LBC, was selected as an appropriate source to inform
158 the clinical and diagnostic probability parameters.

159 The probability of detecting LBC abnormalities and abnormal colposcopy results (CIN1, CIN2 and CIN3)
160 or worse (**Table 1**) were calculated using data from the HORIZON study based on the results for cobas
161 4800 HR-HPV assay (Rebolj et al., 2016, 2015). Methods for calculating the transition probabilities for
162 primary HR-HPV testing are described in detail in a previous model (Weston et al., 2020). HORIZON
163 reported one case of cervical cancer in the study population. Due to the small sample size, this was
164 deemed not suitable for estimating cervical cancer in an entire screening population and therefore CIN3
165 or worse (CIN 3 and cervical cancer, CIN3+) was selected as the most appropriate outcome.

166 Screening coverage (62.6% baseline value) was informed using Flemish screening data (Flemish
167 Department of care, 2021).

168 *Cost inputs*

169 Costs in Belgium were estimated using published data (Annemans et al., 2008a; Fobelets et al., 2015a;
170 RIZIV, 2023a, 2023b, 2023c). All costs (presented in Euros) were inflated to 2023 values (**Table 1**) using
171 the IMF inflation index (CEMG, 2022). The cost of all tests includes sampling and processing costs. The
172 cost of colposcopies and treatment were informed using published literature (Annemans et al., 2008b;
173 Fobelets et al., 2015b). The cost of the initial consultation was taken from RIZIV, a Belgian government

174 agency (RIZIV, 2023a). Costs incurred more than one year in the future were discounted by 3.0%, as
175 recommended by Belgian Healthcare Knowledge Centre (KCE) (Cleemput et al., 2012).

176 As test reimbursement remains uncertain and may vary in different programs and settings, a cost-
177 neutral pricing strategy was developed for co-testing in consultation with experts and is proposed as a
178 potential pricing approach for Belgium. The cost of LBC (€32.41) in the current LBC-based screening
179 algorithm which has a 3-year screening interval is equivalent to €10.80 per year. This yearly cost was
180 used to calculate a cost-neutral price for the co-testing package (HR-HPV and LBC) which has a 5-year
181 screening interval (i.e., $€10.80 \times 5 = €54.02$). The discounting applied when HR-HPV testing and LBC are
182 used for all samples (co-testing) compared to when HR-HPV testing is used for all samples, but LBC is
183 used only for some (HR-HPV primary), is a commercial approach used in the past where two diagnostic
184 tests are used together.

185 Uncertainty analyses

186 *Deterministic sensitivity analyses*

187 Deterministic one-way sensitivity analyses (DSA) were conducted to assess the impact of changing each
188 parameter on the main outcomes. Low and high parameter values were individually varied to generate
189 results (**Supplemental Table 2**). The cost of colposcopy and treatment were varied by 20% to explore
190 potential future variations in costs. The co-testing package cost (co-testing algorithm) was varied by €20;
191 the cost of the HR-HPV test was varied by €20 and LBC by €10 in the HPV-primary algorithm.
192 Probabilities were varied based on the calculated standard error (SE). Those parameters with no SE
193 value assigned were varied by +/- 25% of their baseline values. The low value for loss to follow-up was
194 assumed to be zero, indicating 100% compliance. Tornado plots are used to present the DSA for overall
195 costs, number of colposcopies, HR-HPV, LBC tests and cervical precancer and cancer diagnoses (**Error!**
196 **Reference source not found. Figure 1**). Parameters that impacted the results by $\geq 10\%$ are reported.

197 *Probabilistic sensitivity analysis*

198 Probabilistic sensitivity analysis (PSA) was performed to explore the robustness of results by running the
199 model 1,000 times independently using a Monte Carlo simulation. All input cost parameters were
200 assigned a Gamma distribution, and beta distribution was used for probability inputs from 0 to 1, which
201 were calculated based on estimated alpha and beta values (**Supplemental Table 2, Supplemental Table**
202 **3**). The same values were used for parameters used in both co-testing and HR-HPV primary algorithms
203 (e.g., probability of loss to follow-up for colposcopy). The 95% confidence intervals (CI) were calculated
204 from the results of 1,000 iterations.

205 *Scenario analyses*

206 In the first two scenario analyses, an increased HR-HPV vaccination coverage was assumed (compared to
207 0% in the base case) for women <30 years to simulate HPV vaccinated women entering the screening
208 cohort. The reduced probability of an HR-HPV positive test was calculated using relative risk data from
209 published studies (**Supplemental Table 4**). Scenario 1 represented current vaccination coverage: 67%
210 (Bruni et al., 2023), and Scenario 2, the target coverage: 90% (WHO, 2020b). In Scenario 3, the current
211 reimbursement cost for the HR-HPV test (€67.90) (RIZIV, 2023c) and the LBC cost (€32.41) was used in
212 both screening algorithms.

213 **Results**

214 Baseline results

215 The primary outcomes are presented in **Table 2**. Using the cost-neutral pricing strategy for co-testing,
216 implementing co-testing, which has a different follow-up algorithm (**Figure 1**), would save an average of
217 €11.80 per person screened compared to the HR-HPV primary algorithm. The co-testing algorithm would
218 require an additional 13,173 colposcopies, 67,731 HR-HPV tests and 477,020 LBC tests for the screening
219 cohort (the total programme costs of €58.8M for co-testing and €65.6M for HR-HPV primary in **Table 2**).

220 However, co-testing, would detect an additional 2,351 CIN2+ cases (**Figure 2**), of which 1,602 would be
221 CIN3+ cases, representing an increase of 27.4% and 24.3% respectively. The average cost per CIN2+ case
222 detected was €5,381 for co-testing compared to €7,650 for HR-HPV primary (**Table 4**). Cost outcomes
223 are presented in **Table 3**. The cost of HR-HPV testing contributed the largest component of the total cost
224 in both screening algorithms (81% of total costs in HR-HPV primary and 56% for co-testing) (**Table 3**).
225 The cost of LBC was the second largest contributor to overall costs.

226 Deterministic sensitivity analysis (DSA)

227 The impact of varying each input value between its low and high value are presented in **Supplemental**
228 **Figure 1**. The unit cost of consultation, and of HR-HPV testing and LBC are the main drivers influencing
229 the total cost for both algorithms. Screening coverage was an important driver of the total cost, the total
230 number of colposcopies, LBC, and HR-HPV tests. The probability of CIN3 at 18 months, given a positive
231 HR-HPV test in the HR-HPV primary algorithm or positive results in both tests in the co-testing algorithm
232 at baseline, has an impact on the total number of CIN2+ and CIN3+ cases in both algorithms.

233 Probabilistic sensitivity analysis (PSA)

234 The results of the PSA are shown in **Supplemental Figure 2**. Implementation of the co-testing algorithm
235 led to a greater number of HR-HPV tests, LBC and colposcopies in all iterations compared to the HR-HPV
236 primary algorithm, with a lower total cost in 82.8% of 1,000 iterations. The co-testing algorithm
237 detected more CIN2+ cases in 92.7% and more CIN3+ cases in 87.6% of 1,000 iterations.

238 Scenario analysis

239 Scenario 1 and 2 simulated vaccination coverage of 67% (46,671) and 90% (62,693) of women under 30
240 (69,659). These changes resulted in a decrease in total costs of 1.4% and 1.9% for HR-HPV primary and
241 1.6% and 2.2% for co-testing algorithm, respectively, due to fewer positive HR-HPV tests at baseline.

242 Scenario 3 increased the total cost by 51% compared to using the cost-neutral pricing strategy for co-
243 testing pathway. Total costs for the co-testing pathway were €88.6M compared to the HR-HPV primary
244 pathway total costs of €65.6M. The full results of all scenario analyses are presented in **Supplemental**
245 **Table 7**.

246 **Discussion**

247 Main findings

248 This modelling study compares two hypothetical algorithms for cervical cancer screening in Belgium. The
249 results indicate that, using the algorithms modelled here, co-testing would detect more cervical
250 precancer and reduce the risks of missing cases and potentially save costs when using a cost-neutral
251 approach for pricing the co-testing package. This comes at an increased use of healthcare resources due
252 to the additional diagnostic tests performed. Uncertainty analyses show that the total costs of both
253 algorithms are sensitive to the reimbursement of HR-HPV and LBC tests. Notably, when applying the
254 same reimbursement rates for these tests, the co-testing algorithm becomes more costly compared to
255 the HR-HPV algorithm. These results can provide useful evidence to help inform decisions on shaping an
256 optimal screening strategy in Belgium.

257 Strengths & Limitations

258 While previous economic modelling studies have compared LBC primary and HR-HPV primary screening
259 (Mendes et al., 2015), research comparing co-testing to HPV primary is limited. This is the first study to
260 compare co-testing to HR-HPV primary testing in cervical screening in Belgium. The model was adapted
261 from previously published cervical screening models (Dombrowski et al., 2022; Weston et al., 2021,
262 2020), and adapted to the healthcare system in Belgium.

263 Results from this study align with surveillance data from Germany (co-testing screening) and the
264 Netherlands (HPV primary screening) which provides validation of the model structure and inputs. In the
265 co-testing algorithm, 4.9% of the screening population have colposcopies with 0.5% resulting in the
266 detection of CIN2+ similar to a German co-testing surveillance study reporting approximately 3%
267 ASCUS/AGC or worse results (referral to colposcopy) and 0.5% HSIL or worse (corresponding to CIN2+) in
268 2021 (Xhaja et al., 2022). In the HR-HPV primary algorithm, 2.6% of the screening population have
269 colposcopies with 1.5% resulting in detection of CIN2+. Likewise in 2021, 2.6% of the screening
270 population in the Netherlands underwent colposcopies and CIN2+ was detected in 1.1% (RIVM, 2021).
271 As with any model, assumptions were made regarding the model structure and inputs. As Belgium does
272 not currently use a co-testing clinical algorithm, a hypothetical co-testing algorithm was adapted from
273 co-testing algorithms in Germany and Luxembourg. There were no data on primary HR-HPV screening or
274 co-testing for Belgium, so data from other trials were used (Rebolj et al., 2016, 2015). This has been
275 deemed an appropriate approach for other studies in the absence of applicable data (EUnetHTA, 2015).
276 Since the model uses HORIZON results for the cobas 4800 HR-HPV assay, it simulates the use of this
277 assay, however, the choice of HR-HPV assay used may impact the outcomes, as different assays have
278 different sensitivity and specificity. The reimbursement for tests may change in the implementation of
279 the national programme in Belgium. Sensitivity analyses found the reimbursement of HPV and LBC tests
280 to be key factors in the total cost and cost per precancer detected. However, the impact of varying these
281 values were assessed in uncertainty analyses and indicated that the main conclusions would not change,
282 lending support for the validity of the modelling work.

283 The follow-up periods in the algorithms derived from real-world screening algorithms used in
284 neighbouring countries contribute to the difference in number of CIN2+ and CIN3+ detected between
285 the two alternative screening algorithms (shown in **Supplemental Table 5**). The underlying assumption

286 is the probability of detection of cytological abnormalities increases over time, which may overestimate
287 the difference of CIN2+ numbers between two algorithms.

288 While considering the long-term costs of cancer treatment (co-testing and HR-HPV primary) suggests
289 that co-testing offers improved health and economic outcomes (Felix et al., 2016), the model evaluated
290 the short-term impact of one round of screening including routine screen and follow up and did not
291 include the complexity of disease progression and repeated screening over a lifetime. Taking a simpler
292 approach yields a conservative estimate of the benefits as the true benefits of implementing cervical
293 screening may be underestimated.

294 Future work

295 While it is not necessary to perform a study in Belgium ahead of making decisions to implement a
296 national screening programme, after implementation, the surveillance data from Belgium could be used
297 to validate the results of this study. Moreover, the difference between theoretical and empirical results
298 could be compared, and the model results refined.

299 Studies in Belgium have found lower rates of HR-HPV infections and cervical abnormalities in the
300 vaccinated population (Arbyn et al., 2016). An increasingly vaccinated population entering the cervical
301 screening programme is likely to have a considerable impact due to an overall reduction in HR-HPV
302 prevalence (Lei et al., 2020), but also a strong relative increase of HPV-negative lesions, and a small
303 absolute increase (Falcaro et al., 2021).

304 Additional modelling including disease progression, and consideration of new methods to improve
305 cancer detection such as genotype profiling, DNA methylation, artificial intelligence, will be useful in
306 evaluating the optimal screening algorithm and may trigger changing the screening interval or the
307 testing approach (Bedell et al., 2020; Simms et al., 2017).

308 Conclusion

309 These findings support a co-testing cervical screening algorithm in Belgium if the aim is to maximise the
310 number of women with abnormalities found, minimise the risk of missing cases, and minimise the total
311 cost (compared to a HR-HPV strategy) if a cost-neutral discounted co-testing package price was used.
312 The improved detection of pre-cancerous lesions ensures women receive treatment at the earliest
313 opportunity, reducing more severe treatments and mortality.

References

- 314 Annemans, L., Rémy, V., Lamure, E., Spaepen, E., Lamotte, M., Muchada, J.-P., Largeron, N., 2008a.
315 Economic burden associated with the management of cervical cancer, cervical dysplasia and
316 genital warts in Belgium. *J. Med. Econ.* 11, 135–150.
317 <https://doi.org/10.3111/13696990801961611>
- 318 Annemans, L., Rémy, V., Lamure, E., Spaepen, E., Lamotte, M., Muchada, J.-P., Largeron, N., 2008b.
319 Economic burden associated with the management of cervical cancer, cervical dysplasia and
320 genital warts in Belgium. *Med Econ* 11, 135–150. <https://doi.org/10.3111/13696990801961611>
- 321 Anttila, A., Ronco, G., Clifford, G., Bray, F., Hakama, M., Arbyn, M., Weiderpass, E., 2004. Cervical cancer
322 screening programmes and policies in 18 European countries. *Br. J. Cancer* 91, 935–941.
323 <https://doi.org/10.1038/sj.bjc.6602069>
- 324 Arbyn, M., Broeck, D.V., Benoy, I., Bogers, J., Depuydt, C., Praet, M., Sutter, P.D., Hoorens, A., Hauben,
325 E., Poppe, W., Ranst, M.V., Delvenne, P., Gofflot, S., Péteïn, M., Engelen, F., Vanneste, A., Beeck,
326 L.O.D., Damme, P.V., Temmerman, M., Weyers, S., 2016. Surveillance of effects of HPV
327 vaccination in Belgium. *Cancer Epidemiol.* 41, 152–158.
328 <https://doi.org/10.1016/j.canep.2015.12.011>
- 329 Arbyn, M., Fabri, V., Temmerman, M., Simoons, C., 2014. Attendance at Cervical Cancer Screening and
330 Use of Diagnostic and Therapeutic Procedures on the Uterine Cervix Assessed from Individual
331 Health Insurance Data (Belgium, 2002-2006). *PLOS ONE* 9, e92615.
332 <https://doi.org/10.1371/journal.pone.0092615>
- 333 Arbyn Marc, Haelens Annemie, Desomer Anja, Verdoodt Freija, Francart Julie, Thiry Nancy, Hanquet
334 Germaine, 2015. Quel dépistage pour le cancer du col? (Health Technology Assessment (HTA)
335 No. KCE Reports 238B). Centre Fédéral d'Expertise des Soins de Santé (KCE), Bruxelles.
- 336 Austin R.M., Onisko A., Zhao C., 2018. Enhanced detection of cervical cancer and precancer through use
337 of imaged liquid-based cytology in routine cytology and HPV cotesting. *Am. J. Clin. Pathol.* 150,
338 385–392. <https://doi.org/10.1093/ajcp/aqy114>
- 339 Bedell, S.L., Goldstein, L.S., Goldstein, A.R., Goldstein, A.T., 2020. Cervical Cancer Screening: Past,
340 Present, and Future. *Sex. Med. Rev.* 8, 28–37. <https://doi.org/10.1016/j.sxmr.2019.09.005>
- 341 Blatt, A.J., Kennedy, R., Luff, R.D., Austin, R.M., Rabin, D.S., 2015a. Comparison of cervical cancer
342 screening results among 256,648 women in multiple clinical practices. *Cancer Cytopathol.* 123,
343 282–288. <https://doi.org/10.1002/cncy.21544>
- 344 Blatt, A.J., Kennedy, R., Luff, R.D., Austin, R.M., Rabin, D.S., 2015b. Comparison of cervical cancer
345 screening results among 256,648 women in multiple clinical practices. *Cancer Cytopathol.* 123,
346 282–288. <https://doi.org/10.1002/cncy.21544>
- 347 Bonanni, P., Faivre, P., Lopalco, P.L., Joura, E.A., Bergroth, T., Varga, S., Gemayel, N., Drury, R., 2020. The
348 status of human papillomavirus vaccination recommendation, funding, and coverage in WHO
349 Europe countries (2018–2019). *Expert Rev. Vaccines* 19, 1073–1083.
350 <https://doi.org/10.1080/14760584.2020.1858057>
- 351 Bruni, L., Albero, G., Serrano, B., Mena, M., Collado, J., Gomez, D., Munoz, J., Bosch, F., de Sanjose, S.,
352 2023. Human Papillomavirus and Related Diseases in Belgium. Summary Report. ICO/IARC
353 Information Centre on HPV and Cancer (HPV Information Centre).
- 354 CCEMG, 2022. EPPI-Centre Cost Converter v.1.4 [WWW Document]. URL
355 <https://eppi.ioe.ac.uk/costconversion/default.aspx> (accessed 10.21.22).
- 356 Cleemput, I., Neyt, M., Van de Sande, S., Thiry, N., 2012. Belgian guidelines for economic evaluations and
357 budget impact analyses, 2nd ed, KCE Reports. Belgian Health Care Knowledge Centre (KCE), BE.

- 358 Depuydt, C.E., Leuridan, E., Van Damme, P., Bogers, J., Vereecken, A.J., Donders, G.G.G., 2010.
359 Epidemiology of *Trichomonas vaginalis* and human papillomavirus infection detected by real-
360 time PCR in Flanders. *Gynecol. Obstet. Invest.* 70, 273–280. <https://doi.org/10.1159/000314017>
- 361 Dombrowski, C.A., Weston, G.M., Descamps, P.P., Izopet, P.J., Adams, E.J., Adams, E., 2022. Health
362 economic evaluation of an mRNA high-risk human papillomavirus (HR-HPV) assay versus a DNA
363 HR-HPV assay for the proposed French cervical screening programme. *Medicine (Baltimore)*
364 101, e29530. <https://doi.org/10.1097/MD.00000000000029530>
- 365 EUnetHTA, 2015. Methods for health economic evaluations - A guideline based on current practices in
366 Europe.
- 367 European Commission, 2022. European Health Union: cancer screening [WWW Document]. *Eur. Comm.*
368 - *Eur. Comm.* URL https://ec.europa.eu/commission/presscorner/detail/en/ip_22_5562
369 (accessed 11.30.22).
- 370 Falcaro, M., Castañon, A., Ndlela, B., Checchi, M., Soldan, K., Lopez-Bernal, J., Elliss-Brookes, L., Sasieni,
371 P., 2021. The effects of the national HPV vaccination programme in England, UK, on cervical
372 cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational
373 study. *Lancet Lond. Engl.* 398, 2084–2092. [https://doi.org/10.1016/S0140-6736\(21\)02178-4](https://doi.org/10.1016/S0140-6736(21)02178-4)
- 374 Felix, J.C., Lacey, M.J., Miller, J.D., Lenhart, G.M., Spitzer, M., Kulkarni, R., 2016. The Clinical and
375 Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A
376 Modeling Analysis. *J. Womens Health* 25, 606–616. <https://doi.org/10.1089/jwh.2015.5708>
- 377 Flemish Department of care, 2021. Annual Report on Cancer Population Screening 2021 [WWW
378 Document]. URL [https://www.zorg-en-gezondheid.be/nieuws/jaarrapport-
379 bevolkingsonderzoeken-naar-kanker-2021](https://www.zorg-en-gezondheid.be/nieuws/jaarrapport-bevolkingsonderzoeken-naar-kanker-2021) (accessed 6.13.23).
- 380 Fobelets, M., Pil, L., Putman, K., Annemans, L., 2015a. De kosteneffectiviteit van het
381 bevolkingsonderzoek naar baarmoederhalskanker in Vlaanderen: gezondheidseconomische
382 evaluatie 38.
- 383 Fobelets, M., Pil, L., Putman, K., Annemans, L., 2015b. De kosteneffectiviteit van het
384 bevolkingsonderzoek naar baarmoederhalskanker in Vlaanderen: gezondheidseconomische
385 evaluatie 38.
- 386 Fontham, E.T.H., Wolf, A.M.D., Church, T.R., Etzioni, R., Flowers, C.R., Herzig, A., Guerra, C.E., Oeffinger,
387 K.C., Shih, Y.-C.T., Walter, L.C., Kim, J.J., Andrews, K.S., DeSantis, C.E., Fedewa, S.A.,
388 Manassaram-Baptiste, D., Saslow, D., Wender, R.C., Smith, R.A., 2020. Cervical cancer screening
389 for individuals at average risk: 2020 guideline update from the American Cancer Society. *CA*
390 *Cancer J. Clin.* 70, 321–346. <https://doi.org/10.3322/caac.21628>
- 391 Gov.uk, 2022. Cervical screening: helping you decide [WWW Document]. GOV.UK. URL
392 [https://www.gov.uk/government/publications/cervical-screening-description-in-brief/cervical-
393 screening-helping-you-decide--2](https://www.gov.uk/government/publications/cervical-screening-description-in-brief/cervical-screening-helping-you-decide--2) (accessed 11.23.22).
- 394 Iftner, T., 2021. What is the situation on cervical cancer screening in Germany as an European example?
395 Jansen, E.E.L., Zielonke, N., Gini, A., Anttila, A., Segnan, N., Vokó, Z., Ivanuš, U., McKee, M., de Koning,
396 H.J., de Kok, I.M.C.M., Veerus, P., Anttila, A., Heinävaara, S., Sarkeala, T., Csanádi, M., Pitter, J.,
397 Széles, G., Vokó, Z., Minozzi, S., Segnan, N., Senore, C., van Ballegoijen, M., Driesprong - de Kok,
398 I., Gini, A., Heijnsdijk, E., Jansen, E., de Koning, H., Lansdorp – Vogelaar, I., van Ravesteyn, N.,
399 Zielonke, N., Ivanus, U., Jarm, K., Mlakar, D.N., Primic-Žakelj, M., McKee, M., Priaulx, J., 2020.
400 Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic
401 review. *Eur. J. Cancer* 127, 207–223. <https://doi.org/10.1016/j.ejca.2019.12.013>
- 402 Kaufman, H.W., Alagia, D.P., Chen, Z., Onisko, A., Austin, R.M., 2020. Contributions of Liquid-Based
403 (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical
404 Cancer and Precancer in the United States. *Am. J. Clin. Pathol.* 154, 510–516.
405 <https://doi.org/10.1093/ajcp/aqaa074>

- 406 Lei, J., Ploner, A., Lehtinen, M., Sparén, P., Dillner, J., Elfström, K.M., 2020. Impact of HPV vaccination on
407 cervical screening performance: a population-based cohort study. *Br. J. Cancer* 123, 155–160.
408 <https://doi.org/10.1038/s41416-020-0850-6>
- 409 Maver, P.J., Poljak, M., 2020. Primary HPV-based cervical cancer screening in Europe: implementation
410 status, challenges, and future plans. *Clin. Microbiol. Infect.* 26, 579–583.
411 <https://doi.org/10.1016/j.cmi.2019.09.006>
- 412 Mendes, D., Bains, I., Vanni, T., Jit, M., 2015. Systematic review of model-based cervical screening
413 evaluations. *BMC Cancer* 15, 334. <https://doi.org/10.1186/s12885-015-1332-8>
- 414 Monsonego, J., Bosch, F.X., Coursaget, P., Cox, J.T., Franco, E., Frazer, I., Sankaranarayanan, R., Schiller,
415 J., Singer, A., Wright, T., Kinney, W., Meijer, C., Linder, J., 2004. Cervical cancer control, priorities
416 and new directions. *Int. J. Cancer* 108, 329–333. <https://doi.org/10.1002/ijc.11530>
- 417 Rebolj, M., Bonde, J., Ejegod, D., Preisler, S., Rygaard, C., Lynge, E., 2015. A daunting challenge: Human
418 Papillomavirus assays and cytology in primary cervical screening of women below age 30years.
419 *Eur. J. Cancer* 51, 1456–1466. <https://doi.org/10.1016/j.ejca.2015.04.012>
- 420 Rebolj, M., Bonde, J., Preisler, S., Ejegod, D., Rygaard, C., Lynge, E., 2016. Human Papillomavirus Assays
421 and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above. *PLOS ONE* 11,
422 e0147326. <https://doi.org/10.1371/journal.pone.0147326>
- 423 Rebolj, M., Cuschieri, K., Mathews, C.S., Pesola, F., Denton, K., Kitchener, H., 2022. Extension of cervical
424 screening intervals with primary human papillomavirus testing: observational study of English
425 screening pilot data. *BMJ* 377, e068776. <https://doi.org/10.1136/bmj-2021-068776>
- 426 RIVM, 2021. Monitorbevolkingsonderzoek baarmoederhalskanker 2021 [WWW Document]. URL
427 <https://www.rivm.nl/documenten/monitor-bevolkingsonderzoek-baarmoederhalskanker-2021>
428 (accessed 5.6.22).
- 429 RIZIV, 2023a. Honoraria, prijzen en vergoedingen [WWW Document]. URL
430 [https://www.riziv.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/individuele-
431 verzorging/honoraire/Paginas/default.aspx#:~:text=Het%20verschil%20tussen%20de%20honor
432 aria,een%20overeenkomst%20of%20een%20akkoord.](https://www.riziv.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/individuele-
431 verzorging/honoraire/Paginas/default.aspx#:~:text=Het%20verschil%20tussen%20de%20honor
432 aria,een%20overeenkomst%20of%20een%20akkoord.) (accessed 10.31.22).
- 433 RIZIV, 2023b. Nomensoft: Nomenclatuur en pseudonomenclatuur van de geneeskundige verstrekkingen
434 - 589864 [WWW Document]. Honor. En Vergoedingen Tegemoetkomingen Van Verzek. URL
435 <https://webapps.riziv-inami.fgov.be/Nomen/nl/589864/fees> (accessed 5.23.23).
- 436 RIZIV, 2023c. Nomensoft: Nomenclatuur en pseudonomenclatuur van de geneeskundige verstrekkingen
437 - 588932 [WWW Document]. Honor. En Vergoedingen Tegemoetkomingen Van Verzek. URL
438 <https://webapps.riziv-inami.fgov.be/Nomen/nl/588932/fees> (accessed 7.14.23).
- 439 RIZIV, 2023d. Raadpleging in de spreekkamer door een arts-specialist in de neurologie, inclusief een
440 eventueel schriftelijk.
- 441 Ronco, G., Dillner, J., Elfström, K.M., Tunesi, S., Snijders, P.J.F., Arbyn, M., Kitchener, H., Segnan, N.,
442 Gilham, C., Giorgi-Rossi, P., Berkhof, J., Peto, J., Meijer, C.J.L.M., 2014. Efficacy of HPV-based
443 screening for prevention of invasive cervical cancer: follow-up of four European randomised
444 controlled trials. *The Lancet* 383, 524–532. [https://doi.org/10.1016/S0140-6736\(13\)62218-7](https://doi.org/10.1016/S0140-6736(13)62218-7)
- 445 Secrétariat du Conseil Scientifique, 2019. Dépistage du cancer du col de l’utérus - version longue (2019).
- 446 Simms, K.T., Hall, M., Smith, M.A., Lew, J.-B., Hughes, S., Yuill, S., Hammond, I., Saville, M., Canfell, K.,
447 2017. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-
448 Effectiveness Evaluation for the National Cervical Screening Program in Australia. *PloS One* 12,
449 e0163509. <https://doi.org/10.1371/journal.pone.0163509>
- 450 STATBEL, 2022. Population by place of residence, nationality (Belgian/non-Belgian), marital status, age
451 and gender [WWW Document]. URL
452 [https://bestat.statbel.fgov.be/bestat/crosstable.xhtml?datasource=65ee413b-3859-4c6f-a847-
09b631766fa7](https://bestat.statbel.fgov.be/bestat/crosstable.xhtml?datasource=65ee413b-3859-4c6f-a847-
453 09b631766fa7) (accessed 5.6.22).

- 454 Thiry, N., Gerkens, S., Cornelis, J., Jespers, V., Hanquet, G., 2019. Cost-effectiveness analysis of HPV
455 vaccination of boys in Belgium, KCE Reports. Belgian Health Care Knowledge Centre (KCE), BE.
- 456 Van Kerrebroeck, H., Makar, A., 2016. Cervical cancer screening in Belgium and overscreening of
457 adolescents. *Eur. J. Cancer Prev.* 25, 142–148. <https://doi.org/10.1097/CEJ.000000000000155>
- 458 Vasilyeva, D., Tiscornia-Wasserman, P., Gonzalez, A.A., 2021. Negative Roche cobas HPV testing in cases
459 of biopsy-proven invasive cervical carcinoma, compared with Hybrid Capture 2 and liquid-based
460 cytology. *J. Am. Soc. Cytopathol.* 10, 128–134. <https://doi.org/10.1016/j.jasc.2020.08.006>
- 461 Weston, G., Dombrowski, C., Harvey, M.J., Iftner, T., Kyrgiou, M., Founta, C., Adams, E.J., 2020. Use of
462 the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV
463 assay in the English cervical screening programme: a decision tree model based economic
464 evaluation. *BMJ Open* 10, e031303. <https://doi.org/10.1136/bmjopen-2019-031303>
- 465 Weston, G., Dombrowski, C., Steben, M., Popadiuk, C., Bentley, J., Adams, E.J., 2021. A health economic
466 model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a
467 hypothetical HPV primary screening algorithm in Ontario, Canada. *Prev. Med. Rep.* 23, 101448.
468 <https://doi.org/10.1016/j.pmedr.2021.101448>
- 469 WHO, 2022. Cervical cancer - Key facts [WWW Document]. *Cerv. Cancer*. URL
470 <https://www.who.int/news-room/fact-sheets/detail/cervical-cancer> (accessed 5.30.23).
- 471 WHO, 2020a. Global strategy to accelerate the elimination of cervical cancer as a public health problem.
- 472 WHO, 2020b. Global strategy to accelerate the elimination of cervical cancer as a public health problem
473 [WWW Document]. URL <https://www.who.int/publications-detail-redirect/9789240014107>
474 (accessed 11.8.22).
- 475 Xhaja, A., Ahr, A., Zeiser, I., Ikenberg, H., 2022. Two Years of Cytology and HPV Co-Testing in Germany:
476 Initial Experience. *Geburtshilfe Frauenheilkd.* <https://doi.org/10.1055/a-1886-3311>
- 477 Zorg en Gezondheid, 2021. Jaarrapport bevolkingsonderzoeken naar kanker 2021 [WWW Document].
478 URL [https://www.zorg-en-gezondheid.be/nieuws/jaarrapport-bevolkingsonderzoeken-naar-](https://www.zorg-en-gezondheid.be/nieuws/jaarrapport-bevolkingsonderzoeken-naar-kanker-2021)
479 [kanker-2021](https://www.zorg-en-gezondheid.be/nieuws/jaarrapport-bevolkingsonderzoeken-naar-kanker-2021) (accessed 11.10.22).

Table 1. Key model input parameters baseline values

	Age group	Screening Algorithm	Baseline value	Reference
Demographic				
Screening coverage	Both	Both	62.6%	(Zorg en Gezondheid, 2021)
Total women attending cervical screening	Both	Both	577,846	(STATBEL, 2022; Zorg en Gezondheid, 2021)
Women aged 25-29	<30	Both	69,659	
- Women aged 30-64	≥30	Both	508,187	
Time to recall for a control cytology following a positive co-test at baseline (months)	Both	Co-testing	6	(Iftner, 2021)
Time to recall for a repeat co-test following a positive co-test at baseline (months)	Both	Co-testing	12	
Time to recall for a colposcopy following a positive co-test at baseline (months)	Both	Co-testing	1	
% of HR-HPV negative & LBC positive defined as medium risk at baseline	Both	Co-testing	0.74 ¹	(Rebolj et al., 2016, 2015)
% of colposcopies with biopsy for women who underwent colposcopies	Both	Both	0.0700	(Rebolj et al., 2022)
Loss to follow-up for LBC and co-testing for women who had abnormal screening results	Both	Both	0.3130	(Zorg en Gezondheid, 2021)
Loss to follow-up for colposcopy for women who had abnormal screening results	Both	Both	0.3130	(Blatt et al., 2015b)
Testing and treatment costs (all values in €)				
HR-HPV test	Both	HR-HPV primary	67.90	(RIZIV, 2023b)
LBC test		HR-HPV primary	32.41	(RIZIV, 2023c)
AHR-HPV test plus LBC test	Both	Co-testing ²	54.02 ²	Expert opinion
Follow-up LBC test	Both	Co-testing	32.41	(RIZIV, 2023c)
Colposcopy with biopsy	Both	Both	91.40	(Fobelets et al., 2015b)
Colposcopy without biopsy	Both	Both	34.31	
Cost of consultation in which a swab is taken	Both	Both	23.83	(RIZIV, 2023d)
CIN 1 treatment	Both	Both	284.28	(Annemans et al., 2008b)
CIN 2 treatment	Both	Both	378.47	
CIN 3 treatment	Both	Both	488.32	
Cervical cancer treatment	Both	Both	5,117.43	
Cost annual discount rate	Both	Both	3.0%	(Cleemput et al., 2012)

	Age group	Screening Algorithm	Baseline value	Reference
Clinical and diagnostic probabilities				
Positive HR-HPV test at baseline for all screened women	<30	HR-HPV primary	0.4061	(CCEMG, 2022; Fobelets et al., 2015a)
	≥30	HR-HPV primary	0.1621	
Negative HR-HPV test & negative LBC test at baseline for all screened women	<30	Co-testing	0.5876	(Cleemput et al., 2012)
	≥30	Co-testing	0.8212	
Negative HR-HPV test & positive LBC test at baseline for all screened women	<30	Co-testing	0.7400	(Rebolj et al., 2016, 2015)
	≥30	Co-testing	0.0043	
Positive HR-HPV test & negative LBC test at baseline (medium risk)	<30	Co-testing	0.0046	Assumption
	≥30	Co-testing	0.0124	
Positive HR-HPV test & negative LBC test at baseline for all screened women	<30	Co-testing	0.3380	(Rebolj et al., 2016, 2015)
	≥30	Co-testing	0.1345	
Positive HR-HPV test & positive LBC test at baseline for all screened women	<30	Co-testing	0.0681	
	≥30	Co-testing	0.0275	
CIN 1 at baseline if HR-HPV positive at baseline for all screened women	<30	HR-HPV primary	0.1964	
	≥30	HR-HPV primary	0.1724	
CIN 2 at baseline if HR-HPV positive at baseline for all screened women	<30	HR-HPV primary	0.1429	
	≥30	HR-HPV primary	0.1379	
CIN 3 at baseline if HR-HPV positive at baseline for all screened women	<30	HR-HPV primary	0.4464	
	≥30	HR-HPV primary	0.5000	
Cervical cancer at baseline if HR-HPV positive at baseline for all screened women	<30	HR-HPV primary	0 ³	
	≥30	HR-HPV primary	0 ³	

Abbreviations: CIN, Cervical squamous intraepithelial neoplasia; DSA, Deterministic sensitivity analysis; LBC, Liquid-based cytology; HR-HPV, High-risk human papillomavirus.

¹Total low grade LBC results (74% of all with baseline HR-HPV negative and LBC abnormal results) were calculated from the LBC results ((a typical squamous cells of undetermined significance (ASCUS) (48%) and low-grade squamous intraepithelial lesions (LSIL) (26%)) of those with and baseline HR-HPV negative results in the HORIZON data.

²The cost of a co-testing package (HR-HPV and LBC test) performed at a screening interval of 5 years, €54.02, was calculated from the annual cost of an LBC test at a screening interval of 3 years of €32.41.

³ No cases of cervical cancer were reported in the HORIZON study for those with positive cobas HR-HPV tests at baseline.

Only key probability input parameters which have larger impact on primary results have been presented in this table; a complete list of input parameters is presented in Error! Reference source not found..

480

Table 2. Primary outcomes under baseline assumptions for HR-HPV primary and co-testing algorithms for cervical screening (cohort N=577,846)

Screening Algorithm	Total programme cost (€)	Cost per screen (€)	Number of colposcopies	HR-HPV tests	LBC tests	CIN2+ diagnoses	CIN3+ diagnoses
Co-testing	58,775,083	101.7	28,055	645,577	652,555	10,924	8,199
HR-HPV primary	65,588,573	113.5	14,882	577,846	175,535	8,573	6,597

Abbreviations: CIN, Cervical squamous intraepithelial neoplasia; HR-HPV, Human papillomavirus.

Table 3. Secondary outcomes under baseline assumptions for HR-HPV primary and co-testing algorithms for cervical screening (cohort N=577,846).

Screening Algorithm	Colposcopies (€)	HR-HPV tests (€)	LBC tests (€)	CIN 1 treatment (€)	CIN 2 treatment (€)	CIN 3+ treatment (€)
Co-testing	1,071,664	32,811,275	17,825,880	1,510,269	1,030,170	4,525,826
HR-HPV primary	569,078	53,005,826	7,233,726	810,690	747,902	3,221,352

Abbreviations: CIN – Cervical squamous intraepithelial neoplasia; HR-HPV – Human papillomavirus. CIN 3+ includes cost of treatment of CIN 3 and cervical cancer.

Table 4. Average cost (€) and number of colposcopies per CIN 2+ and CIN 3+ case for HR-HPV primary and co-testing algorithms for cervical screening

Screening Algorithm	Average cost per CIN2+ case (€)	Average cost per CIN3+ case (€)	Average number of colposcopies per CIN2+ case
Co-testing	€5,381	€7,169	2.6
HR-HPV primary	€7,650	€9,942	1.7

Abbreviations: CIN – Cervical squamous intraepithelial neoplasia; HR-HPV – Human papillomavirus.

Figure 1. HR-HPV primary and co-testing screening pathways




Figure 1. Number of CIN2 and CIN3+ cases diagnosed by screening algorithm

